Paul Peter Tak sold $3.2M of CADL
Chief Executive Officer at Candel Therapeutics, Inc.. 280,245 shares at an average of $11.28, traded Sep 10, 2026, filed Sep 11, 2026.
Score components
- +25RoleCEO
- +25Trade size$3.2M at market
- +20Share of holdings soldSold 71% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001873905-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | MOption exercise Common Stock10b5-1 | +125,000 | $1.55 | $194k | 393,566 | 31 d ago |
| Sep 10, 2026 | SOpen-market sale Common Stock10b5-1 | -220,866 | $11.50 | $2.5M | 172,700 | 31 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -59,379 | $10.46 | $621k | 113,321 | 31 d ago |
| Sep 10, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -125,000 | $0.00 | $0 | 1,638,968 | 31 d ago |
Related signals
Other insiders at Candel Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $6,540 937 shares | -2% | |
| 0Weak | Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $3,936 781 shares | -1% | |
| 14Weak | Candel Therapeutics, Inc. | Francesca Barone Chief Scientific Officer | $282k 32,146 shares | -25% | |
| 38Weak | Candel Therapeutics, Inc. | Paul Peter Tak Chief Executive Officer | $230k 26,172 shares | -10% | |
| 21Weak | Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $397k 45,316 shares | -46% | |
| 21Weak | Candel Therapeutics, Inc. | Charles Schoch See Remarks | $44k 5,000 shares | -12% | |
| 19Weak | Candel Therapeutics, Inc. | Seshu Tyagarajan Chief Technology Officer | $276k 31,278 shares | -27% | |
| 45Moderate | Candel Therapeutics, Inc. | Francesca Barone Chief Scientific Officer | $98k 13,534 shares | -11% | |
| 43Moderate | Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $75k 10,428 shares | -12% | |
| 51Moderate | Candel Therapeutics, Inc. | Paul Peter Tak Chief Executive Officer | $157k 21,704 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.